Results Published from a Phase 3 Trial of Daclizumab High-Yield Process (DAC HYP) in Relapsing MS


  • A Phase 3 study involving 1,841 people with relapsing-remitting MS showed that Daclizumab high-yield process (DAC HYP) reduced the rate of relapses by 45% compared to Avonex® (interferon beta-1a, Biogen), and also reduced disease activity observed on MRI scans over the course of 2 to 3 years.
  • Participants were randomly assigned to receive either DAC HYP injected under the skin every 4 weeks or Avonex injected once weekly for up to 144 weeks. Participants also received placebo versions of Avonex or DAC HYP as a…

    Favicon of da :

    Prosegui la lettura...
    Traduci l'articolo...

    Sclerosi Multipla News

    Potrebbe interessarti anche

Argomenti correlati